Paratek Pharmaceuticals, Inc. Reports First Quarter 2015

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Paratek Pharmaceuticals, Inc. Reports First Quarter 2015 Financial and Operating Results
  • Follow-on offering accelerates oral-only indication development and extends funding through top line results of the Phase 3 CABP clinical trial, expected in mid-2017
  • Initiation of the first Phase 3 clinical trial for omadacycline in acute bacterial skin and skin structure infections on-track to start mid-2015

BOSTON, May 15, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK ), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today reported financial results for the first quarter period ended March 31, 2015.

"With our recently completed financing, we are well positioned to advance our lead antibiotic candidate, omadacycline, into Phase 3 clinical trials mid-year, first in acute bacterial skin and skin structure infections (ABSSSI) and, later this year in community-acquired bacterial pneumonia (CABP)," noted Michael Bigham, Chief Executive Officer, Paratek. "We are also now able to accelerate our clinical development plans for a third important potential indication in urinary tract infections (UTI)."

Financial Results

For the Three Months Ended March 31 st , 2015 as Compared to the Same Quarter 2014

For the quarter ended March 31, 2015, Paratek reported a net loss of $10.6 million, or $0.74 per share, compared to a net loss of $1.4 million, or $20.93 per share, for the quarter ended March 31, 2014.

No revenue was reported for the first quarter of 2015 as compared to $48,000 in research and development collaboration revenue for the same period in 2014.

Research and development expenses for 2015 were $6.7 million, an increase of $6.2 million compared to the same quarter 2014. The change was primarily the result of preparation for our planned Phase 3 clinical trials of omadacycline as well as higher compensation, recruiting and other personnel-related costs. General and administrative expenses for the quarter ended March 31, 2015 were $4.3 million, a $2.0 million increase compared to the same period in 2014 primarily due to increases in professional and consulting services (e.g., legal, accounting, and audit), compensation, recruiting and other personnel-related costs.

At March 31, 2015, Paratek had cash and cash equivalents of $92.5 million. The subsequently completed underwritten offering of 3,089,000 shares of common stock at a public offering price of $24.50 per share on May 5, 2015 yielded $70.7 million in aggregate proceeds, after underwriting discounts and commissions and other estimated offering expenses. The net proceeds from this offering, together with existing cash, will fund ongoing and planned clinical trials of omadacycline, research and development to advance preclinical candidates, and for working capital and other general corporate purposes.

Based on current assumptions, the company's cash and cash equivalents are expected to fund operations through mid-2017, expected to coincide with the availability of top-line data from the second of two planned Phase 3 trials of omadacycline (CABP).

About Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is an aminomethycycline, derived from tetracyclines. Omadacycline is a new broad-spectrum antibiotic being developed in both once-daily oral tablet and intravenous formulations for potential use as a as monotherapy for ABSSSI, CABP, UTI and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern. Omadacycline has received Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Paratek has Special Protocol Assessment agreements with the FDA for the Phase 3 trials planned in ABSSSI and CABP.

Paratek's second product candidate, sarecycline, also known as WC 3035, is a new once-daily oral tetracycline-derived compound, designed to provide both a narrow-spectrum of antibiotic activity and favorable tolerability profile, for the treatment of acne and rosacea in the community setting. Paratek has licensed rights to sarecycline for the treatment of acne in the United States to a subsidiary of Actavis, formerly Warner Chilcott, while retaining rights in the rest of the world. Actavis is responsible for the clinical development of sarecycline for the treatment of acne in the United States. A Phase 3 program was initiated by Actavis in December 2014 for sarecycline for the treatment of moderate to severe acne.

 
PARATEK PHARMACEUTICALS, INC.
SELECTED FINANCIAL INFORMATION
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands, except loss per share data)
 
   Quarter Ended
March 31, 2015
Quarter Ended
March 31, 2014
Revenue  $ --  $ 48
Operating expenses:    
Research and development  6,741  526
General and administrative  4,271  453
Impairment of intangible asset  2,761  --
Changes in fair value of contingent consideration  (3,140)  --
Total operating expenses  10,633  979
Loss from operations  (10,633)  (931)
Other income and expenses, net  --  (280)
Net loss  (10,633)  (1,211)
Unaccreted dividends on convertible preferred stock  --  202
Net loss attributable to common stockholders  $ (10,633)  $ (1,413)
Net loss per share, basic and diluted    
basic and diluted  $ (0.74)  $ (20.93)
Weighted average common shares outstanding    
basic and diluted  14,418,145  67,500
     
     
PARATEK PHARMACEUTICALS, INC.
SELECTED FINANCIAL INFORMATION
Condensed Consolidated Balance Sheets
(in thousands)
     
  March 31, December 31,
  2015 2014
  (unaudited)  
     
Cash  $ 92,510  $ 95,856
Total assets  99,701  109,967
Current liabilities  7,284  3,741
Long-term obligations, less current portion  7,569  11,002
Common stock and additional paid-in capital  293,347  293,090
Accumulated deficit  (208,499)  (197,866)
Total stockholders' equity  99,701  109,967
     

Forward Looking Statements

This press release contains forward-looking statements including statements related to our overall strategy, product candidates, clinical trials, cash resources, prospects and expected results, including statements about our advancing our lead antibiotic candidate into clinical trials and otherwise preparing for clinical trials, our having the resources to execute on our clinical trials, expand operational capabilities and address unmet need for patients and society, the use of proceeds of our public offering and the period our cash and cash equivalents are expected to fund operations. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "believe," "expect," "well positioned," "look forward," "anticipated," "continued," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to our need for substantial additional funding to complete the development and commercialization of our product candidates, risks related to our ability to raise the capital that we believe to be accessible and is required to fully finance the development and commercialization of our product candidates, risks relating to our ability to develop our drug candidates for potential commercialization, the timing of the commencement of omadacycline Phase 3 trials, the potential for omadacycline to be successfully developed for use as a first-line empiric monotherapy for patients suffering from serious community-acquired bacterial infections, the potential of omadacycline to become the primary antibiotic choice of physicians for the treatment of serious community-acquired bacterial infections, the potential use and effectiveness of sarecycline for the treatment of acne and rosacea in the community setting, and the timing of the commencement of a Phase 3 program in moderate-severe acne for sarecycline , risks that data to date and trends may not be predictive of future results, risks related to the conduct of our clinical trials, and risks that our clinical trials may not receive regulatory approval. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

Media: Michael Lampe (484) 575-5040 Investors: Hans Vitzthum LifeSci Advisors, LLC. (212) 915-2568

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 98

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 70

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
Frost & Sullivan’s 65 Years Put APAC Growth on Display

Updated Category News Views 25

A Crowded Singapore Room Says Something Singapore did not host a mere anniversary toast on November 18; it hosted a pretty revealing cross-section of the businesses trying to build, secure, cool, connect, finance, and digitize Asia Pacific and MEASA. Frost & Sullivan marked 65 years with its 2026 Best Practices Recognition banquet at Hilton Singapore Orchard, gathering...

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 30

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Shareholder Votes Clear ODNB-NACB Merger's Final Hurdle

Updated Category News Views 69

A merger vote rarely makes anyone pound the table, but it does remove one very real way a bank deal can stumble. ODNB Financial Corporation and National Capital Bancorp, Inc. have announced that their shareholders approved the proposed merger. That is meaningful progress, plain and simple. It says the owners who get to live with the outcome have signed off on joining the...

Continue Reading
SwitchBot's Black Friday Sale Tests Smart Home Demand

Updated Category News Views 147

Holiday gadget season is where clever home-tech pitches either earn their keep or gather dust in a warehouse. SwitchBot is coming into Black Friday 2026 with discounts of up to 50% on select products, running from November 19 through Cyber Monday on November 30. The lineup is broad enough to matter: decorative color E Ink frames, automated curtains and blinds, an indoor...

Continue Reading
Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 71

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 91

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 118

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Candel’s BLA Delay Puts Disclosure Timing Under Fire

Updated Category News Views 118

A December filing turned into a mid-2027 wait, and Candel shareholders absorbed the damage in one ugly trading session. On November 13, shares of Candel Therapeutics fell 26% after the company disclosed that its biologics license application, or BLA, for aglatimagene in prostate cancer was no longer expected in December 2026. The revised plan is to submit in the middle of...

Continue Reading

Top 5 Most Recently Viewed Articles

Uncovering Surveillance Pricing: Consumer Watchdog's New Insights

Updated Category News Views 124

Understanding Surveillance Pricing in Today's Market As we continue to navigate the digital landscape, a new and concerning practice has emerged within the retail and e-commerce sectors — surveillance pricing. This strategy allows corporations to charge different prices to consumers for the same item based on their personal data and online behavior, as highlighted by...

Continue Reading
Understanding Voting Rights and Capital at Albion Technology

Updated Category News Views 136

Total Voting Rights and Capital Overview Albion Technology & General VCT PLC In accordance with Disclosure Guidance and Transparency Rule 5.6.1, we at Albion Technology & General VCT PLC are providing key insights into our voting rights and capital structure. Issued Share Capital Details As of the recent update, the issued share capital and voting rights of the Company...

Continue Reading
Hisense Unveils Cutting-Edge Smart Home Solutions at IFA

Updated Category News Views 130

Transforming Everyday Living with Hisense Smart Technology Leading the way in home technology, Hisense recently showcased a range of innovative smart home solutions designed to enhance daily living at the IFA 2024 trade show. As a prominent name in consumer electronics, Hisense is committed to elevating the smart living experience for users worldwide. Hisense's Dedication...

Continue Reading
Jeffs’ Brands Enters Strategic Agreement for Security Tech Expansion

Updated Category News Views 296

Exploring New Horizons: Jeffs’ Brands' Non-Binding MOU The 3D, AI-Powered Technology Screens 25,000 People Per Hour—Without Stopping Them In an exciting development for Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (NASDAQ: JFBR, JFBRW), a leading data-driven e-commerce firm leveraging the Amazon Marketplace, the company has announced its wholly owned...

Continue Reading
Garmin and Global Researchers Unveil Groundbreaking Happiness Study

Updated Category News Views 175

Introduction to the Health and Happiness Study Garmin, known for its innovative technology, has embarked on an exciting journey in collaboration with researchers from prestigious institutions aimed at understanding the intricate relationship between technology, happiness, and wellbeing. This Health and Happiness Study represents a significant step forward in the quest to...

Continue Reading